YSS is not a good buy right now for a Beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is in a clear technical downtrend, sentiment is weakened by the contract-cancellation/news flow, and both proprietary signals are absent. Even though some analysts still see upside over time, the current setup favors waiting rather than buying immediately.
Current price is 23.84, down 17.76% in regular trading and another 6.70% pre-market, which shows strong negative momentum. MACD is negative and expanding, confirming bearish trend pressure. RSI_6 at 24.743 indicates the stock is deeply oversold, but not yet showing a confirmed reversal. Moving averages are converging, which usually happens during transition periods, but price is still below the pivot at 31.055 and below resistance at R1 36.652 and R2 40.109. Near-term pattern data also points weakly negative over the next week and month. Overall trend: bearish.

Analysts continue to maintain positive or neutral-to-bullish long-term views, with several Buy/Outperform ratings still in place. Jefferies sees potential re-rating as sales ramp materializes, JPMorgan highlighted confidence in contract progress, and the company reported 9.5% revenue growth to $116.34 million with backlog at $642 million. The backlog and commercial booking progress are the main fundamental positives.
News flow is negative overall: Pomerantz is investigating possible securities fraud and governance issues, and the stock fell sharply after the Pentagon contract cancellation. The company also reported a very large net loss of $114.84 million in the latest quarter, raising profitability concerns. Analysts have been cutting price targets recently, and there are worries about heavy reliance on Pentagon contracts, shareholder dilution, and acquisition-related financial stress.
Latest quarter: Q1 2023. Revenue increased 9.5% year over year to $116.34 million, which is a healthy top-line growth sign. However, the company posted a net loss of $114.84 million, which is very weak and suggests profitability remains a major issue. Backlog improved to $642 million, supporting future demand visibility, but the earnings quality is currently poor because growth is not translating into profits.
Analyst sentiment is mixed but still leaning constructive on the long term. Recent target changes show multiple downgrades/cuts: Goldman raised target to $31 but kept Neutral, Citi cut to $33 but kept Buy, Truist lowered to $26 and kept Hold after an earnings miss, Jefferies lowered to $34 and kept Buy, JPMorgan lowered to $38 and kept Overweight, and Needham lowered to $33 while keeping Buy. Wall Street pros see a scalable space-defense platform, strong backlog, and potential re-rating, but cons include backlog pressure, reliance on government contracts, earnings misses, and weaker near-term visibility.